Iron toxicity in hematopoietic stem cell transplantation: Strike while the iron is labile

Acta Haematologica

Volumn 131, Issue 4, 2014, Pages 220-221

  Pullarkat, Vinod ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; HEPCIDIN; IRON; TRANSFERRIN; FERRITIN;

ADVERSE OUTCOME; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; INFECTION RISK; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; LIVER VENOOCCLUSIVE DISEASE; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETICULOCYTE COUNT; TREATMENT OUTCOME; ACUTE LEUKEMIA; BONE MARROW APLASIA; CANCER RISK; FERRITIN BLOOD LEVEL; HEMOGLOBINOPATHY; MYELODYSPLASTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY;

FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON; IRON OVERLOAD; MALE; TRANSPLANTATION CONDITIONING;

EID: 84901366800     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000355827     Document Type: Note

References (9)

1. Sivgin S, Eser B: Management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: where do we stand? Ann Hematol 2013; 92: 577-586.
2. Pullarkat V: Iron overload in patients undergoing hematopoietic stem cell transplantation. Adv Hematol 2010; 2010:pii345756.
3. Sahlstedt L, Ebeling F, von Bonsdorff L, Parkkinen J, Ruutu T: Non-transferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol 2001; 113: 836-838. (Pubitemid 32524411)
4. Durken M, Nielsen P, Knobel S, Finckh B, Herrnring C, Dresow B, Kohlschutter B, Stockschlader M, Kruger WH, Kohlschutter A, Zander AR: Nontransferrin-bound iron in serum of patients receiving bone marrow transplants. Free Radic Biol Med 1997; 22: 1159-1163. (Pubitemid 27171957)
5. Kanda J, Mizumoto C, Kawabata H, Tsuchida H, Tomosugi N, Matsuo K, Uchiyama T: Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica 2008; 93: 1550-1554.
6. Naoum FA, Esposito BP, Ruiz LP, Ruiz MA, Tanaka PY, Sobreira JT, Cancado RD, de Barros JC: Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation. Acta Haematologica 2014; 131:222-226.
7. Von Bonsdorff L, Sahlstedt L, Ebeling F, Ruutu T, Parkkinen J: Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron. FEMS Immunol Med microbiol 2003; 37: 45-51. (Pubitemid 36588927)
8. Parkkinen J, Sahlstedt L, von Bonsdorff L, Salo H, Ebeling F, Ruutu T: Effect of repeated apotransferrin administrations on serum iron parameters in patients undergoing myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2006; 135: 228-234. (Pubitemid 44401621)
9. Ramos E, Ruchala P, Goodnough JB, Kautz L, Preza GC, Nemeth E, Ganz T: Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 2012; 120: 3829-3836.